Applied Genetic Technologies opens for trade at $12.75, IPO priced at $12.00 Applied Genetic Technologies (AGTC) priced 4.17M shares at $12.00. BMO Capital and Wedbush acted as joint book running managers for the offering.
Applied Genetic, 4D Molecular Therapeutics sign collaboration agreement Applied Genetic and 4D Molecular Therapeutics announced a collaboration and license agreement to discover and develop optimized AAV vectors to treat specific ophthalmic disease indications with high unmet medical need. As part of the agreement, 4DMT will deploy its proprietary AAV vector discovery platform, Directed Vector Evolution, to identify and optimize novel vectors. Financial details were not disclosed.